| Literature DB >> 26647745 |
Nayara Y Tamburus1, Roberta F L Paula2, Vandeni C Kunz3, Marcelo C César4, Marlene A Moreno2, Ester da Silva1.
Abstract
BACKGROUND: Autonomic dysfunction and inflammatory activity are involved in the development and progression of coronary artery disease (CAD), and exercise training has been shown to confer a cardiovascular benefit.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26647745 PMCID: PMC4668337 DOI: 10.1590/bjpt-rbf.2014.0124
Source DB: PubMed Journal: Braz J Phys Ther ISSN: 1413-3555 Impact factor: 3.377
Figure 1Flowchart showing patient participation in the study. CAD-T= trained group with patients with coronary artery disease; CAD-C= control group with patients with coronary artery disease; RF-T= trained group with patients with cardiovascular risk factors; RF-C= control group with patients with cardiovascular risk factors.
Baseline clinical characteristics of the trained and control groups.
|
|
|
| ||
|---|---|---|---|---|
|
|
|
|
| |
| Age (years) | 58.9±4.0 | 56.2±7.4 | 56.3±6.2 | 60.4±6.1 |
|
| ||||
| Myocardial infarction | 0(0.0%) | 4(33.3%) | 0(0.0%) | 2(20.0%) |
| Coronary artery bypass surgery | 0(0.0%) | 4(33.3%) | 0(0.0%) | 4(40.0%) |
| Percutaneous coronary intervention | 0(0.0%) | 8(66.6%) | 0(0.0%) | 6(60.0%) |
|
| ||||
| Beta blockers | 4(40.0%) | 7(58.3%) | 4(40.0%) | 5(50.0%) |
| ACE inhibitors | 3(30.0%) | 7(58.3%) | 7(70.0%) | 4(40.0%) |
| Hypolipidemic agents | 5(50.0%) | 10(83.3%) | 2(20.0%) | 8(80.0%) |
| Diuretics | 1(20.0%) | 3(25.0%) | 2(20.0%) | 2(20.0%) |
| Antiplatelet agents | 4(40.0%) | 10(83.3%) | 6(60.0%) | 9(90.0%) |
| Hypoglycemic agents | 0(0.0%) | 1(8.3%) | 2(20.0%) | 2(20.0%) |
|
| ||||
| Smoking | 1(10.0%) | 3(25.0%) | 3(30.0%) | 1(10.0%) |
| Sedentary lifestyle (IPAQ) | 10(100.0%) | 12(100.0%) | 10(100.0%) | 10(100.0%) |
| Dyslipidemia | 7(70.0%) | 10(83.3%) | 3(30.0%) | 9(90.0%) |
| Hypertension (140/90 mHg) | 5(50.0%) | 8(66.6%) | 7(70.0%) | 7(70.0%) |
| Obesity (BMI ≥ 30 kg/m2) | 1(10.0%) | 5(41.6%) | 3(30.0%) | 3(30.0%) |
| Diabetes mellitus | 0(0.0%) | 1(8.3%) | 2(20.0%) | 2(20.0%) |
|
| ||||
| Triglycerides (mg/dL) | 119.9±59.1 | 154.2±70.0 | 138.8±44.4 | 153.1±74.0 |
| Total cholesterol (mg/dL) | 177.7±46.7 | 172.2±50.1 | 164.8±24.0 | 171.6±22.1 |
| Fasting glucose (mg/dL) | 93.2±7.5 | 98.2±10.9 | 90.0±10.0 | 97.2±12.1 |
| HDL cholesterol (mg/dL) | 48.1±20.1 | 40.7±10.5 | 39.9±11.6 | 39.1±9.8 |
| LDL cholesterol (mg/dL) | 97.2±29.5 | 105.6±34.3 | 100.7±17.9 | 98.7±26.4 |
|
| ||||
| VO2(mL.kg-1.min-1) | 14.5±2.4 | 13.50±2.14 | 14.38±2.06 | 13.15±3.33 |
| VO2 (L.min-1) | 1.15±0.24 | 1.12±0.25 | 1.14±0.28 | 1.08±0.20 |
| HR (bpm) | 105.6±15.1 | 106.9±12.7 | 115.7±22.3 | 103.4±24.4 |
| Workload (W) | 82.6±28.0 | 80.2± 6.8 | 84.3±24.3 | 81.7±17.3 |
Values are represented as mean ± SD, except where indicated. CAD = coronary artery disease; RF = risk factor; ACE = angiotensin converting enzyme; IPAQ = International Physical Activity Questionnaire; HDL = high-density lipoprotein; LDL = low-density lipoprotein; VO2 = oxygen consumption; HR = heart rate; bpm = beats per minute; W = watts.
Figure 2Visual presentation of intensity levels and duration performed during of interval training. VAT= ventilatory anaerobic threshold.
Hemodynamic variables at rest, heart rate variability indices, and high-sensitivity C-reactive protein levels of the groups studied.
|
|
|
|
| |||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |||||||||
| Height (cm) | 169(7) | - | - | 169(8) | - | - | - | - | ||
| Weight (kg) | 79.2(8.8) | 78.0(12.6) | 0.03 | 0.26 | 74.0(21.0) | 77.5(24.6) | 0.30 | 0.05 | 0.73 | 0.73 |
| BMI (kg/m2) | 26.7(2.5) | 26.1(2.7) | 0.03 | 0.41 | 26.3(5.6) | 27.5(5.4) | 0.30 | 0.14 | 0.79 | 0.73 |
| SBP (mmHg) | 130(17.5) | 120(7.5) | 0.03 | 0.67 | 127(9.5) | 130(11.2) | 0.05 | 0.53 | 0.85 | 0.01 |
| DBP (mmHg) | 85(10) | 80(3.7) | 0.03 | 0.76 | 89(10) | 88(8.7) | 0.22 | 0.33 | 0.85 | 0.008 |
| HR (bpm) | 61(17) | 67(11) | 0.79 | 0.03 | 63(11) | 66(14) | 0.08 | 0.41 | 0.91 | 0.57 |
| Spectral and symbolic indices | ||||||||||
| LF (nu) | 0.55(0.24) | 0.46(0.24) | 0.28 | 0.36 | 0.63(0.39) | 0.73(0.07) | 0.20 | 0.62 | 0.68 | 0.002 |
| HF (nu) | 0.44(0.24) | 0.53(0.24) | 0.28 | 0.36 | 0.36(0.39) | 0.26(0.07) | 0.20 | 0.62 | 0.68 | 0.002 |
| 0V% | 29.2(20.2) | 14.7(19.6) | 0.009 | 0.67 | 25.0(10.5) | 31.1(9.2) | 0.24 | 0.22 | 0.63 | 0.01 |
| 2UV% | 16.8(10.5) | 24.2(14.3) | 0.005 | 0.76 | 12.2(23.4) | 10.3(6.1) | 0.18 | 0.64 | 0.73 | 0.01 |
| Inflammatory marker | ||||||||||
| hs-CRP (mg/dL) | 0.18(1.0) | 0.04(0.05) | 0.01 | 0.37 | 0.55(0.72) | 1.15(1.02) | 0.009 | 1.05 | 0.27 | 0.008 |
| CAD-T (n= 12) | CAD-C (n= 10) | |||||||||
| Height (cm) | 167(12.2) | - | - | 171(10.5) | - | - | - | - | ||
| Weight (kg) | 82(23.7) | 79(26.0) | 0.03 | 0.28 | 86.5(16.4) | 85.5(15.5) | 0.93 | 0.02 | 0.82 | 0.65 |
| BMI (kg/m2) | 29.0(5.7) | 29.3(4.9) | 0.04 | 0.23 | 27.9(4.1) | 28.4(6.4) | 0.49 | 0.08 | 0.82 | 0.80 |
| SBP (mmHg) | 130(10) | 120(2.5) | 0.005 | 0.86 | 130(23.7) | 140(17.5) | 0.03 | 0.40 | 0.34 | 0.14 |
| DBP (mmHg) | 90(10) | 80(2.5) | 0.01 | 1.09 | 85(10) | 90(10) | 0.42 | 0.22 | 0.49 | 0.04 |
| HR (bpm) | 63(13) | 72(12) | 0.15 | 0.52 | 60(9) | 57(6) | 0.06 | 0.24 | 0.45 | 0.97 |
| Spectral and symbolic indices | ||||||||||
| LF (nu) | 0.61(0.31) | 0.58(0.13) | 0.23 | 0.35 | 0.60(0.22) | 0.55(0.21) | 0.28 | 0.24 | 0.45 | 0.87 |
| HF (nu) | 0.38(0.31) | 0.41(0.13) | 0.23 | 0.35 | 0.39(0.22) | 0.44(0.21) | 0.28 | 0.24 | 0.45 | 0.87 |
| 0V% | 35.7(29.6) | 25.9(13.5) | 0.09 | 0.50 | 22.5(14.2) | 25.4(17.1) | 0.07 | 0.61 | 0.10 | 0.82 |
| 2UV% | 12.5(9.7) | 19.0(13.0) | 0.004 | 0.71 | 21.2(27.1) | 16.2(13.1) | 0.05 | 0.58 | 0.10 | 0.67 |
| Inflammatory marker | ||||||||||
| hs-CRP (mg/dL) | 1.2(1.1) | 0.7(0.6) | 0.01 | 0.63 | 0.9(0.5) | 1.1(0.4) | 0.006 | 0.43 | 0.18 | 0.22 |
Data are presented as median (interquartile range). RF-T = risk factor-trained; CAD-T = coronary artery disease-trained; RF-C = risk factor-control; CAD-C = coronary artery disease-control; ES= effect size; BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = heart rate at rest; LF= low frequency; HF= high frequency; nu= normalized units; 0V% = percentage of pattern with no variation; 2UV% = percentage of pattern with two unlike variations; hs-CRP = high-sensitivity C-reactive protein. Significance level of p<0.02.
Analysis of covariance (ANCOVA) and linear regression analysis of HRV indices and hs-CRP and the covariates for the trained and control groups.
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| FT-T | 0V% | Beta blocker | 0.02 | 28.96 | -14.69 | 0.51 |
| CAD-T | 0V% | Beta blocker | 0.05 | 38.03 | -17.43 | 0.65 |
| ACE inhibitor | 0.03 | -12.78 | ||||
| Dyslipidemia | 0.005 | 10.14 | ||||
| Hypertension | 0.01 | 18.41 | ||||
| 2UV% | Beta blocker | 0.02 | 9.78 | 10.74 | 0.62 | |
| ACE inhibitor | 0.05 | 11.22 | ||||
| Dyslipidemia | 0.007 | -5.65 | ||||
| hs-CRP | ACE inhibitor | 0.04 | 1.17 | -9.25 | 0.50 | |
| Hypolipidemic | 0.03 | -0.18 | ||||
| PCI | 0.01 | -0.20 | ||||
| RF-C | 2UV% | Beta blocker | 0.04 | 48.07 | -3.41 | 0.69 |
| Hypertension | 0.02 | 3.20 | ||||
| Obesity | 0.05 | 3.15 | ||||
| CAD-C | 0V% | Dyslipidemia | 0.02 | 48.24 | 20.41 | 0.64 |
| Hypertension | 0.03 | 11.84 | ||||
| Obesity | 0.04 | 0.85 |
r2 = coefficient of determination; 0V% = percentage of pattern with no variation; 2UV% = percentage of pattern with two unlike variations; hs-CRP = high-sensitivity C-reactive protein; ACE = angiotensin-converting enzyme; RF-T = risk factor-trained; CAD-T = coronary artery disease-trained; RF-C = risk factor-control; CAD-C = coronary artery disease-control; PCI = percutaneous coronary intervention; ANCOVA and linear regression. Significance level of p<0.05.